98%
921
2 minutes
20
Background: At least six different mathematical models of cancer and their countless variations and combinations have been published to date in the scientific literature that reasonably explain epidemiological prediction of multi-step carcinogenesis.] Background: At least six different mathematical models of cancer and their countless variations and combinations have been published to date in the scientific literature that reasonably explain epidemiological prediction of multi-step carcinogenesis. Each one deals with a particular set of problems at a given organizational level ranging from populations to genes. Any of the models adopted in those articles so far do not account for both epidemiological and molecular levels of carcinogenesis.
Methods: We have developed a mathematically rigorous system to derive those equations satisfying the basic assumptions of both epidemiology and molecular biology without incorporating arbitrary numerical coefficients or constants devoid of any causal explanation just to fit the empirical data. The dataset we have used encompasses 21 major categories of cancer, 124 selected populations, 108 cancer registries, 5 continents, and 14,067,894 individual cases.
Results: We generalized all the epidemiological and molecular data using our derived equations through linear and non-linear regression and found all the necessary coefficients to explain the data. We also tested our equations against non-neoplastic conditions satisfying equivalent mathematical assumptions.
Conclusion: Our findings show that the new mathematical framework effectively bridges epidemiological and molecular data on carcinogenesis. Validated across various cancer types and extended to non-neoplastic conditions, this unified approach lays a strong foundation for future integrative cancer research.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12303294 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0328401 | PLOS |
JCO Glob Oncol
May 2025
Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Purpose: Breast cancer remains a significant public health challenge globally, as well as in India, where it is the most frequently diagnosed cancer in females. Significant disparities in incidence, mortality, and access to health care across India's sociodemographically diverse population highlight the need for increased awareness, policy reform, and research.
Design: This review consolidates data from national cancer registries, global cancer databases, and institutional findings from a tertiary care center to examine the epidemiology, clinical challenges, and management gaps specific to India.
PLoS One
September 2025
Department Chemicals and Product Safety, German Federal Institute for Risk Assessment (BfR), Berlin, Germany.
Tattoos and permanent make-up (PMU) gain increasing popularity among the general population. There are indications that pigments or their fragments may translocate within the body, however knowledge about possible systemic adverse effects related to tattoos is very limited. We investigated the prevalence of systemic chronic health effects including cardiovascular diseases, cancer and liver toxicity and their relationship with the presence and characteristics of tattoos and PMU as part of the LIFE-Adult-study, a population-based cohort study.
View Article and Find Full Text PDFJ Cancer Res Clin Oncol
September 2025
Institute for Community Medicine, Section Epidemiology of Health Care and Community Health, University Medicine Greifswald, Greifswald, Germany.
Purpose: The German sector-based healthcare system poses a major challenge to continuous patient monitoring and long-term follow-up, both essential for generating high-quality, longitudinal real-world data. The national Network for Genomic Medicine (nNGM) bridges the inpatient and outpatient care sectors to provide comprehensive molecular diagnostics and personalized treatment for non-small cell lung cancer (NSCLC) patients in Germany. Building on the established nNGM infrastructure, the DigiNet study aims to evaluate the impact of digitally integrated, personalized care on overall survival (OS) and the optimization of treatment pathways, compared to routine care.
View Article and Find Full Text PDFAntimicrob Agents Chemother
September 2025
GSK, Collegeville, Pennsylvania, USA.
Gepotidacin, a novel, bactericidal, first-in-class triazaacenaphthylene antibacterial, was noninferior to nitrofurantoin in two pivotal trials (EAGLE-2 and EAGLE-3) in females with uncomplicated urinary tract infections (uUTIs). Using pooled data, gepotidacin activity and clinical efficacy were evaluated for subsets of molecularly characterized isolates in the microbiological Intent-to-Treat population. The subsets of isolates were characterized based on phenotypic/MIC criteria; all microbiological failure isolates were also characterized.
View Article and Find Full Text PDFmBio
September 2025
Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, Washington, USA.
Accurate timing estimates of when participants acquire HIV in HIV prevention trials are necessary for determining antibody levels at acquisition. The Antibody-Mediated Prevention (AMP) Studies showed that a passively administered broadly neutralizing antibody can prevent the acquisition of HIV from a neutralization-sensitive virus. We developed a pipeline for estimating the date of detectable HIV acquisition (DDA) in AMP Study participants using diagnostic and viral sequence data.
View Article and Find Full Text PDF